Rocket Pharmaceuticals (RCKT) Other financing activities (2015 - 2024)

Rocket Pharmaceuticals has reported Other financing activities for 8 years, with the latest figure at $321000.0 in Q4 2024.

• Quarterly Other financing activities fell 85.57% year-over-year to $321000.0 in Q4 2024, while the trailing twelve-month figure through Sep 2025 was $321000.0 (down 93.72% YoY) and the FY2024 annual result came in at $3.2 million, up 43.93% from the prior year.
• Other financing activities advanced to $321000.0 in Q4 2024 per RCKT's latest filing, from $176000.0 in the prior quarter.
• Over five years, Other financing activities peaked at $280.8 million in Q4 2020 and troughed at -$10.2 million in Q4 2021.
• A 5-year average of $19.1 million and a median of $631000.0 in 2022 frame the typical range for Other financing activities.
• The widest YoY moves for Other financing activities: up 37066.67% in 2021, down 103.63% in 2021.
• Over 5 years, Other financing activities stood at $280.8 million in 2020, then plunged by 103.63% to -$10.2 million in 2021, then soared by 106.19% to $631000.0 in 2022, then soared by 252.46% to $2.2 million in 2023, then sank by 85.57% to $321000.0 in 2024.
• According to Business Quant data, Other financing activities over the past three periods registered $321000.0, $176000.0, and $1.5 million for Q4 2024, Q3 2024, and Q2 2024 respectively.